Maturity onset diabetes of the young and fibrin-related thrombosis risk

RC Sagar¹, F Phoenix¹, G Thanabalasingham², K Naseem¹, RA Ajjan¹* and KR Owen²,³*

Abstract

Background: Fibrin network characteristics determine predisposition to cardiovascular disease (CVD). Individuals with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) have higher risk of CVD and display deranged fibrin network structure. Those with maturity onset diabetes of the young (MODY) may also be at increased risk but their fibrin clot properties have not been studied.

Methods: Plasma clots properties from 13 individuals with HNF1A-MODY, 12 matched-individuals with T2DM and 12 with T1DM were studied using a validated turbidimetric assay and confocal microscopy. Plasma levels of fibrinogen, plasminogen activator inhibitor-1, complement C3 and C-reactive protein were also measured.

Results: MODY clot maximum absorbance was 0.37 ± 0.03 AU, similar to T1DM (0.32 ± 0.03 AU; p = 0.26), but lower than T2DM (0.49 ± 0.03 AU; p = 0.02), with confocal microscopy confirming structural differences. Clot lysis time in MODY was similar to T1DM (456 ± 50 and 402 ± 20 s, respectively; p = 0.09) but shorter than T2DM (588 ± 58 s; p = 0.006). Comparing inflammatory/thrombotic proteins in HNF1A-MODY and T2DM, C3 levels were lower in MODY than T2DM (0.58 ± 0.09 and 0.80 ± 0.1 mg/ml, respectively; p < 0.01).

Conclusions: HNF1A-MODY fibrin network alterations are at least as pronounced as in T1DM but less thrombotic than T2DM clots. Differences in fibrin clot characteristics comparing HNF1A-MODY and T2DM may, in part, relate to lower C3 levels.

Keywords

MODY, fibrinolysis, thrombosis, clot structure

Introduction

Whilst cardiovascular complications are recognised as significant contributors to morbidity and mortality in patients with both type 1 (T1DM) and type 2 diabetes (T2DM),¹,² far less is known about the risk in maturity onset diabetes of the young (MODY). MODY is group of monogenic disorders of β-cell function, leading to reduced insulin secretion and diabetes with a predominantly pancreatic phenotype.³,⁴ It is estimated that MODY is the cause of around 2% of patients with diabetes, although this may be as high as 5%, particularly as the diagnosis is often delayed or missed.⁴ Whilst the percentage of individuals with MODY is relatively small, the actual number of these patients is significant with a prevalence of at least 1 in 10,000 in the adult population. Despite this, little is known about the cardiovascular risk in these patients and how their outcomes compare with macrovascular complications in both type 1 and type 2 diabetes. Limited studies suggest that risk of vascular complications is increased in individuals with MODY compared to individuals without diabetes except for those with glucokinase gene mutation who display no or minimal increase in risk.⁵ A Finnish cohort of HNF1A-MODY had similar levels of microvascular complications to T1DM and T2DM when matched for diabetes duration and glucose control assessed as glycated haemoglobin (HbA1c).
The prevalence of coronary artery disease (CAD) appeared to be midway between T1DM and T2DM, although the T2DM group were significantly older. In another study, Irish patients with HNF1A-MODY had the same prevalence of CAD as a matched T1DM group.

We have previously shown that fibrin clot properties, in particular fibrin clot lysis, predicts vascular risk and clinical outcome in individuals with diabetes. In this pilot study we hypothesise that clot structure is altered in individuals with the commonest form of MODY, due to pathogenic variants in HNF1A, which in turn may be one mechanism for the enhanced risk of vascular complications in this population. Therefore, in this work we compare clot structure parameters and key coagulation protein plasma levels in individuals with HNF1A-MODY to those with T1DM and T2DM, groups with known increased vascular risk compared to the healthy population.

Materials and methods

For the study, 13 volunteers with known MODY due to an HNF1A variant from the MODY in Oxford Study (REC A 06/Q1604/136) were studied. Twelve individuals each with T2DM and T1DM, matched for age and HbA1c, were also recruited. The individuals with T2DM were recruited from the Young Diabetes in Oxford study (REC A 04 Q1604 97) and individuals with T1DM from Leeds (REC 09 H1307 12). After informed consent, morning blood samples were collected in sodium citrate (3.8%) and centrifuged within 2 h of collection to separate plasma. All plasma samples were stored at –80°C until required for analysis. Clinical data were also recorded.

Clot structure was studied in all these samples using a validated turbidimetric assay as previously described. Clot final turbidity, used as a measure of clot density, was recorded. We also investigated time from full clot formation to 50% lysis as a marker of lysis potential as well as clot lysis area, a complex measure of clot formation and lysis. Clots generated ex vivo were visualised using confocal microscopy, as previously described elsewhere. Plasma levels of fibrinogen and plasminogen activator inhibitor-1 (PAI-1) along with inflammatory proteins, C-reactive protein (CRP) and complement-3 (C3) were analysed by enzyme-linked immunosorbent assay (ELISA) as previously described.

All statistical analyses were conducted using PRISM 8.3.1. ANOVA was used comparing the three groups with unpaired t-test for comparing two groups.

Results

Our baseline characteristics are outlined in Table 1 and shows that the groups were well matched for age, gender, BMI and HbA1c.

|                  | T1DM (n=12) | MODY3 (n=13) | T2DM (n=12) | p value |
|------------------|-------------|--------------|-------------|---------|
| Mean age (range) | 26 (19–41)  | 36 (19–51)   | 36 (21–52)  | 0.96    |
| Male/Female      | 6/6         | 6/7          | 5/7         | 0.68    |
| BMI              | 25.5 ± 1.6  | 26.3 ± 1.6   | 27.6 ± 2.2  | 0.71    |
| HbA1c (%)        | 7.8 ± 0.3   | 7.1 ± 0.4    | 7.6 ± 0.5   | 0.44    |
| Sys BP (mmHg)    | 133 ± 5     | 131 ± 7      | 122 ± 5     | 0.30    |
| Dias BP (mmHg)   | 73 ± 3      | 77 ± 4       | 77 ± 3      | 0.74    |
| Smoker (%)       | 17%         | 18%          | 18%         | 0.44    |
| On statin (%)    | 8%          | 23%          | 42%         | 0.16    |
| On aspirin (%)   | 0%          | 8%           | 8%          | 0.60    |
| On insulin (%)   | 100%        | 39%          | 50%         | 0.004   |

|                  | T1DM        | MODY3       | T2DM        | p value |
|------------------|-------------|-------------|-------------|---------|
| Mean age (range) | 26 (19–41)  | 36 (19–51)  | 36 (21–52)  | 0.96    |
| Male/Female      | 6/6         | 6/7         | 5/7         | 0.68    |
| BMI              | 25.5 ± 1.6  | 26.3 ± 1.6  | 27.6 ± 2.2  | 0.71    |
| HbA1c (%)        | 7.8 ± 0.3   | 7.1 ± 0.4   | 7.6 ± 0.5   | 0.44    |
| Sys BP (mmHg)    | 133 ± 5     | 131 ± 7     | 122 ± 5     | 0.30    |
| Dias BP (mmHg)   | 73 ± 3      | 77 ± 4      | 77 ± 3      | 0.74    |
| Smoker (%)       | 17%         | 18%         | 18%         | 0.44    |
| On statin (%)    | 8%          | 23%         | 42%         | 0.16    |
| On aspirin (%)   | 0%          | 8%          | 8%          | 0.60    |
| On insulin (%)   | 100%        | 39%         | 50%         | 0.004   |

T1DM: type 1 diabetes, MODY: maturity onset diabetes of the young, T2DM: type 2 diabetes, BMI: body mass index, Sys BP: systolic blood pressure, Dias BP: diastolic blood pressure.

Values given as mean ± SEM or percentages.
The largest lysis time was observed with T2DM (409 ± 56 AU), which was significantly elevated compared to T1DM (p < 0.01) and MODY (p = 0.04). The differences seen between the three groups was also statistically significant, p = 0.002 as shown in Figure 1(a).

**Thrombotic and inflammatory proteins**

Our data have so far shown that plasma clot structure from individuals with MODY is largely similar to that of T1DM, but significantly different compared with T2DM. To understand potential mechanisms for the observed differences between MODY and T2DM groups, we next examined plasma levels of key thrombotic and inflammatory proteins. Fibrinogen, plasminogen activator inhibitor (PAI)-1, C-reactive protein (CRP) and complement C3. In contrast, complement-3 (C3) levels, an inflammatory protein with antifibrinolytic properties, were lower in the MODY group compared with T2DM (0.58 ± 0.09 vs 0.80 ± 0.1, p < 0.01; Figure 1(b)).
Confocal imaging

We next imaged the clot structure in pooled samples from the MODY and T2DM groups. The images demonstrate a tighter plasma clot structure from T2DM plasma compared with plasma (Figure 1(c)), consistent with the differences observed on turbidimetric assays.

Conclusion

Our data suggest that individuals with HNF1A-MODY have a prothrombotic plasma clot structure that is at least similar to those with T1DM but it differs significantly compared to individuals with T2DM. It can be argued that MODY patients display an intermediate fibrin structure phenotype, sitting between T1DM and T2DM individuals, supported by data from clot lysis area but numbers are limited to make concrete conclusions. Taken together, our findings indicate increased thrombosis risk in MODY that is likely to contribute to their vascular risk.

Given the clear differences observed between MODY and T2DM patients, we investigated potential mechanisms and demonstrate this is not related to fibrinogen or PAI-1 plasma levels. Interestingly, C3 plasma levels were found to be significantly lower in MODY compared with T2DM. Given the possible effects of C3 on clot structure and fibrinolysis, whereby it binds to fibrin and is incorporated into the clot resulting in prolonged fibrinolysis as well as the role of HNF1A-MODY in modulation of terminal complement proteins, this may be one mechanism by which to explain the differences seen between our patients with HNF1A-MODY and those with T2DM. Alternatively, it is possible that HNF1A-MODY patients display alternative post-translational modification of plasma proteins, particularly fibrinogen, which may account for the observed differences in fibrin network structure, measured by the turbidimetric assay and visualised by confocal microscopy.

The main strengths of the study are the investigation of clot structure in HNF1A-MODY, which has not been undertaken before and the well-matched groups of patients. Also, we used a validated turbidimetric assay to study clot structure and further visualised the clot by confocal microscopy to confirm the findings. In addition, our data suggest that reduction of complement C3 levels may be a protective mechanism in HNF1A-MODY against the formation of more thrombotic clots.

The main limitation to our study is the relatively small cohort of subjects involved. The findings are therefore preliminary, but could point to differences between the diabetes types. As a cross-sectional study, causality (i.e. clot structure contributing to vascular events) was not measured, but our evidence suggests prospective outcome studies are warranted. More work is needed to understand the mechanistic pathways responsible for the differences in clot structure parameters comparing HNF1A-MODY and T2DM. HNF1A is a transcription factor, regulating expression of a large number of hepatic genes including the key clotting molecules prothrombin, fibrinogen as well as the terminal clotting factors C5 and C8. This may lead to unique effects on clot formation in HNF1A-MODY. Finally, as we only studied one type of MODY, our observations may not be generalisable to other forms of monogenic diabetes.

In summary, we demonstrate that fibrin-related thrombosis risk in MODY is at least as high as in T1DM, but does not reach the risk level seen in T2DM. Our work indicates that further research, with a greater number of participants, is warranted into evaluating fibrin network properties in MODY and how this contributes to vascular outcome. Studies are also required to analyse other types of MODY and mechanistic pathways responsible for the observed changes in fibrin network structure, which may offer novel treatment strategies to reduce the risk of thrombosis in this population.

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RCS: Nil; FP: Nil; GT: Nil; KN: Nil; KA: Nil; RAA: Institutional Research Grants from Abbott, Bayer, Eli Lilly, Novo Nordisk, Roche, Takeda as well as honoraria/education support/Consultancy from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk and Takeda.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

RC Sagar https://orcid.org/0000-0001-7972-3321

References

1. Bulugahapitiya U, Siyambalapitiya S, Sithole J, et al. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009; 26(2): 142–148.
2. Pajunen P, Koukkunen H, Ketonen M, et al. Myocardial infarction in diabetic and non-diabetic persons with and without prior myocardial infarction: the FINAMI Study. Diabetologia 2005; 48(12): 2519–2524.
3. Owen KR. Monogenic diabetes: old and new approaches to diagnosis. Clin Med (Lond) 2013; 13(3): 278–281.
4. Shields BM, Hicks S, Shepherd MH, et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010; 53(12): 2504–2508.
5. Steele AM, Shields BM, Wensley KJ, et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA 2014; 311(3): 279–286.
6. Isomaa B, Henriksson M, Lehto M, et al. Chronic diabetic complications in patients with MODY3 diabetes. *Diabetologia* 1998; 41(4): 467–473.
7. Bacon S, Kyithar MP, Rizvi SR, et al. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort. *Diabet Med* 2016; 33(7): 976–984.
8. Alzahrani SH, Hess K, Price JF, et al. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. *J Clin Endocrinol Metab* 2012; 97(12): E2282–E2287.
9. Sumaya W, Wallentin L, James SK, et al. Impaired fibrinolysis predicts adverse outcome in acute coronary syndrome patients with diabetes: a PLATO sub-study. *Thromb Haemost* 2020; 120(3): 412–422.
10. Soedamah-Muthu SS, Fuller JH, Mulnier HE, et al. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. *Diabetes Care* 2006; 29(4): 798–804.
11. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. *Diabetes Care* 2014; 37(10): 2843–2863.
12. Hess K, Alzahrani SH, Mathai M, et al. A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. *Diabetologia* 2012; 55(4): 1103–1113.
13. Neergaard-Petersen S, Larsen SB, Grove EL, et al. Imbalance between fibrin clot formation and fibrinolysis predicts cardiovascular events in patients with stable coronary artery disease. *Thromb Haemost* 2020; 120(1): 75–82.
14. Hooper JM, Stuijver DJ, Orme SM, et al. Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals. *J Clin Endocrinol Metab* 2012; 97(5): 1463–1473.
15. Hess K, Alzahrani SH, Price JF, et al. Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3. *Diabetologia* 2014; 57(8): 1737–1741.
16. Howes JM, Richardson VR, Smith KA, et al. Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. *Diab Vasc Dis Res* 2012; 9(3): 216–225.
17. Pontoglio M, Pausa M, Doyen A, et al. Hepatocyte nuclear factor 1alpha controls the expression of terminal complement genes. *J Exp Med* 2001; 194(11): 1683–1689.